CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Parkinson's disease - Evidence
Supporting evidence
- Evidence on anti-parkinsonian drugs has not been summarized in this CKS topic because these drugs are started in secondary care. An outline of the use of anti-parkinsonian drugs is given in Confirmed Parkinson's disease: secondary care.
- Evidence on antidepressant drugs in people with Parkinson's disease has been summarized here because:
- There is a role for primary care in the management of the non-motor symptoms of Parkinson's disease, in particular depression [Parkinson's Disease Society, 2007].
- It is hypothesized that the effectiveness of different classes of antidepressants may differ between people with and without Parkinson's disease [Frisina et al, 2008b].
© NHS Institute for Innovation and Improvement